Life Sciences Archive » February, 2017

Life Sciences - February, 2017

320 articles

• Lincare Dodges FCA Claims But Not Retaliation Allegations
• Health Care Fund Seeks Class Cert. In Celexa, Lexapro MDL
• Fed. Circ. Says PTAB Wrongly Nixed Patent In Eli Lilly Case
• FDA Warning Wire: Cardboard Parts Found In Pfizer Vials
• Pfizer Sues Ex-Marketing Director Over Trade Secret Theft
• 9th Circ. Won't Revive Spine Device False Claims Act Suit
• FDA Finally Addresses Interchangeable Biosimilars
• Cutting Labeling Regs May Harm Companies' Bottom Lines
• Complying With Expanded Access Policy Drug Laws
• How 401(k) Benefits Can Attract Millennial Legal Talent
• GC Whistleblowing And Other Implications From Bio-Rad
• How The Courts Review Executive Orders
• Conn. Man Cops To Bribery Over NJ Medical Device Contract
• Fresenius Dialysis Drug Didn't Kill Patient, Jury Told
• Cause Of Death Testimony OK'd In Meningitis Outbreak Trial
• Medical Supply Wholesaler Faces TCPA Suit Over Junk Faxes
• Perrigo Inks $2.85B Divestiture Amid Activist Pressure
• Feds Blast Drug Return Co.'s 'Puffery' Defense In $116M Fraud
• Eli Lilly, Pfizer Urge Fed. Circ. To Undo Sanofi IP Ruling
• Lab Exec Fights 'Hitler' Comparison In FCA Retaliation Suit
• South Texas Woman Convicted In $2.5M Medicaid Fraud
• When The Learned Intermediary Is A Physician's Assistant
• High Court's Patent Guidance On Exporting Component Parts
• Supreme Court Won't Hear 'Flanax' Foreign Trademark Case
• The Loss Of Confidentiality In NY Arbitral Enforcement Cases
• US Weighs In On High Court Biosimilars Battle
• Hernia Patch Death Suit Tossed For Lack Of Experts
• Cynosure Investors Sue To Block $1.4B Hologic Merger
• Animal Groups Sue Over 'Orwellian' Removal Of USDA Docs
• PTAB Invalidates 2 Anacor Patents In Hedge Fund Challenge
• Insurer Needn't Cover Catalent's $10M Shutdown Loss Claim
• 'Black-Box Medicine' Faces Headwinds Over Med Mal Liability
• Medtronic Hit With NJ Suit Over Shoddy Placement Of Device
• Health Hires: Squire Patton Boggs, Lando & Anastasi, Barnes
• What Lawyers Can Learn From Kellyanne Conway
• J&J Talc Plaintiff Just Learned Key Cancer Details, Jury Hears
• Bio-Rad Agrees To $3.5M Fees In Ex-GC Firing Case
• InspireMD Beats Finder's Fee Bid Over $24M, For Now
• Spectrum Pharma Investors Sue Over Rejected FDA Advice
• Impax Investor Drops Suit Over Drug Price-Fixing Probe
• 'Puffery' Isn't Fraud, Says Drug Return Co. In $116M Case
• Andrews, Gainey To Be CytRx Stock-Pump Suit Lead Counsel
• Ex-Valeant, Philidor Execs Deny $40M Kickback Scheme
• Law360 Life Sciences Editorial Advisory Board
• Opioid Addiction Treatment Co. Pulls $150M IPO
• Merck Sued In Philly Over Shingles Vaccine Injuries
• Final Anti-Dumping Duties On Chinese Refrigerants Decided
• The Mistakes Lawyers Make When Copying And Pasting
• Tax Implications Of The Affordable Care Act Repeal
• Talc Studies Don't Merit User Warning, J&J Consultant Says
• Invokana Patients Lose Bid To Remand Kidney-Damage Suit
• High Court Overseas Patent Law Ruling Will Spur More Fights
• Atty In NFLer's Stock Scheme Says Insurer Owes For Defense
• Jana Scores Board Seats At Tiffany & Co., Bristol-Meyers
• NJ Pharma Co. Settles Bias Suit From Ex-Global Study Leader
• Cleveland Clinic Revives Heart-Disease Test Patent Row
• AbbVie Wants Out Of Testosterone MDL Before Bellwethers
• PTAB Upholds Pozen Patent In Kyle Bass Challenge
• Calif. Court Gets Automatic Funding Disclosure Right
• Fed. Circ. Provides Cautionary Tale On Markush Claiming
• Pharmacist, Wife Took In $20M Before Meningitis Outbreak
• Theranos' Arizona Lab Sanctioned For Quality Control Issues
• States' Suboxone Product-Hop Claims Fail, Indivior Says
• CPSC Agrees To Issue Toy Safety Regs After 2-Year Delay
• Mylan Can't Shield Docs In $100M Tax Fight Over Drug License
• Biotech CEO Nixes Bid To Pull Plea For Funneling Shares
• Baxter, Hospira Call Saline Price-Fixing Claims Illogical
• Pa. Judge Again Trims Essure Injury Claims Against Bayer
• Scientists Ask 11th Circ. To Nix $10.6M Fraud Conviction
• Less FDA Review May Boost Medical Device Plaintiff Awards
• Justices Limit Reach Of Law On Overseas Patent Infringement
• J&J Plaintiff Didn't Test For Cancer Risk Genes, Jury Hears
• Lidoderm Buyers, End Payors Win Cert. In Pay-For-Delay MDL
• Fed. Circ. Affirms PTAB Nix Of Depomed Drug-Release Patent
• 6th Circ. Upholds Abbott Labs' Depakote Birth Defect Win
• Immunomedics Attacks Investor Proxy Efforts In Del. Suit
• High Court Declines Czech Republic Suit Over $325M Award
• FDA Warning Wire: Pfizer Lapse Boosts Teva Blockbuster
• Deals Rumor Mill: Aramco, Toshiba, Sinochem
• Chemical Overload Killed Fresenius Patient, Jury Told
• Par Gets PTAB Review Of Afinitor Patent
• Supreme Court Won't Hear Law Firm's Avandia Fund Dispute
• Feds Push Back At Exhibits In Meningitis Murder Trial
• Syngenta MDL Class Counsel Want Other Firms To Butt Out
• Health Care Deal Predictions From '17 JP Morgan Conference
• Shkreli, Ex-Katten Atty Seek To Split Criminal Cases
• Impax Says FTC Should Pay For Withdrawn Pay-For-Delay Suit
• Supreme Court Won't Hear $308M Boston Scientific Appeal
• Jurors In Toxic Tort Litigation Take Genetics Seriously
• Del. High Court's Volcano Ruling Confirms Corwin's Potency
• How The GDPR Will Impact Life Sciences And Health Care
• 9th Circ. Doubts Timeliness Of Amgen Off-Label Sales Suit
• Jury Finds Man Traded On Inside Info About Sanofi Deal
• 4 Cos. Agree To $14.8M Deal To Clean Up Ill. Superfund Site
• Ex-Neurostar Investors Say Buyer Is Holding On To Escrow
• Biosimilar Notice Ruling 'Nonsensical,' High Court Hears
• Snapchat's $3B IPO Leads Rebounding Tech Market
• Merck Settles Long-Running Pay-For-Delay Suit
• Becton Asks Justices Not To Revive $340M Antitrust Award
• Ex-Playboy Bunny Accuses Sex Pill Maker Of Fake Promo
• Kimberly-Clark Wants Investor Suit Over Gowns Tossed
• Pharmacist Rebuts Key Testimony In Meningitis Murder Trial
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Taxation With Representation: Weil, Skadden, Kirkland
• Jury Finds Chinese Scientist Guilty In Stolen Seeds Plot
• Breast Implant Fight Should Stay In Court, Brazilian Co. Says
• Amgen Hiding Biosimilar Info, Genentech Suit Says
• Echo Investors Get Fee Bid Slashed In 'Slam Dunk' Case
• Pfizer Prevails In 2 W.Va. Zoloft Birth Defect Suits
• Atty's Widow Can't Prove GSK Meant To Harm, Judge Says
• Sofia Vergara Sues Ex-Fiancé In Dispute Over Pre-Embryos
• Immunomedics Will Turn Over Sale Documents To Investors
• 11th Circ. Affirms Toss Of Dispute Over Enbrel Use
• Watson Wants Lidoderm Suit Stayed For Ruling On FTC Power
• Bugs And Hair Plagued Meningitis-Linked Pharmacy, Jury Told
• Hospital Slams Bids To Ax $10M Pepcid Patent Verdict
• Life Sciences Group Of The Year: White & Case
• 2nd Circ. Actos Ruling Boosts Pharma Antitrust Plaintiffs
• Coherus Says IP Covering Mega-Drug Humira Is 'Obvious'
• When Personal Jurisdiction And Alter Ego Collide
• Relearning The Lessons Of Korematsu's Case
• Next Steps After Broad Institute's Big Gene-Editing Patent Win
• How A General Counsel Should Think About AI: Part 2
• Dr. Reddy's Generic Infringes Aloxi Patents, Judge Rules
• J&J Tells Jury Talc Is Warning-Free, Like Alcohol, Red Meat
• PTAB Sees No Overlap In Rival Schools' Gene-Editing Patents
• Meningitis-Linked Drugmaker Was On States' Radar, Jury Told
• Ariosa Urges Fed. Circ. Not To Review AIA Estoppel Provision
• FTC Chair Says She'll Seek Balance In IP Antitrust Cases
• Sunovion Gets 2 Latuda Generics Blocked, Sues Over A 3rd
• Insurers Fight Cancer Center Dismissal Bid In Data Breach
• Ex-Cohen Milstein Attys Launch New Group At Motley Rice
• Med-Mal Jury Charge Didn't Force Verdict, NJ Panel Says
• Judge Steps Back From Lilly Investor Suit Over Ropes & Gray
• Latham Guides Integra In $1B Offer For J&J Neurosurgery Unit
• Life Sciences Group Of The Year: Mayer Brown
• How A General Counsel Should Think About AI: Part 1
• 10 Years Of MedImmune: How License Agreements Changed
• Cancer Survivor's Tissue Nearly Talc-Free, J&J Tells Jury
• Arthrex, Smith & Nephew Settle Suture Anchor Patent Row
• FDA Warning Wire: FDA Denied Docs At Chinese Plant
• Major Cos. Back New Group Aimed At Educating Public On IP
• Judge Urged To Keep Boston Scientific Mesh Cases Moving
• Immunomedics Investor Says Board Avoiding Director Election
• Roxane's PTAB Challenge To Afinitor Patent Comes Up Empty
• Hologic Expands Into Medical Aesthetics With $1.65B Buy
• Life Sciences Group Of The Year: King & Spalding
• Pfizer, Flynn Appeal £89M Fines Over UK Epilepsy Drug Prices
• Long-Arm Jurisdiction In Missouri And Beyond: Part 2
• 10 Years Of MedImmune: What Trademark Owners Learned
• Medtronic Dodges Spine Device FCA Suit, For Now
• Valeant, Ackman Ink Allergan Litigation Management Deal
• Saving Lawyers 1 Less Drink At A Time
• Illinois lawmakers propose biotechnology tax credits
• New FDA Enforcement Stats Show Shifting Targets
• DHS Must Scrutinize Bio Attacker ID Abilities, Report Says
• NJ Whistleblower Denied Shares Of States' FCA Settlements
• Long-Arm Jurisdiction In Missouri And Beyond: Part 1
• Sessions Could Further Blunt Bank Access For Pot Biz
• Deals Rumor Mill: Stada, Popeye's, Syneron
• Egalet Hit With 2nd Investor Suit Over Abuse-Deterrent Label
• Buyers Want Patent Suit Docs In Asacol Antitrust Suit
• Wellbutrin Buyers Tell 3rd Circ. Actos Ruling Bolsters Case
• Debevoise Guides Allergan In $2.47B Zeltiq Buy
• Life Sciences Group Of The Year: Goodwin Procter
• 10 Years Of MedImmune: How Patent Owners Fared
• What To Know About HHS Revised 'Common Rule'
• Lawyers Cannot Stay Silent While Trump Belittles The Courts
• Talc Lobbyists Stymied Carcinogen Classification, Jury Hears
• Del. Plaintiffs Bar Rattled By Seismic Shift In Merger Law
• Regeneron Subpoenaed Over Patient Assistance Nonprofits
• Par Can't Shake Antitrust Suit Over Vasopressin Access
• BIO, PhRMA Back Call For Fed. Circ. To Broaden AIA Estoppel
• Energy Rebound Leads Capital Markets As Health Care Fades
• Sanofi Says Amphastar, Ex-K&L Atty Doctored Evidence
• Ethicon Asks 4th Circ. To Rethink $3M Pelvic Mesh Verdict
• Sandoz Kicks Off Supreme Court Biosimilar Battle
• Fresenius Doctor Grilled Over Label On Dialysis Drug
• GSK Moves To Cut Willfulness From Reed Smith Suicide Trial
• FDA Warns Of Potential Obesity Stomach Balloon Issues
• 1st Circ. Gauges Antitrust Immunity In Enoxaparin Row
• Life Sciences Group Of The Year: Covington & Burling
• Ex-Insys Sales Boss Indicted In Fentanyl Kickback Scheme
• Fed. Circ. Clears Actavis In Generic Lialda Patent Suit
• How Tom Price Is Being Welcomed As HHS Secretary
• Marketing Basics For Solo Practitioners And Small Law Firms
• Nearly 30 Senate Dems Sign On To Scientific Integrity Bill
• 10 Years Of MedImmune: The Fed. Circ. Decisions
• Senate Confirms Price For HHS Secretary
• 9th Circ. Urged To Revive Spine Device FCA Suit
• Clovis Cancer-Drug Class Action Survives Dismissal Bid
• Feds Look To Intervene In 20-State Drug Antitrust Suit
• Wash. High Court Says Intuitive Had Duty To Warn Hospital
• J&J Hid Talc Risk For 'Love Of Money,' Jury Hears
• GCs May Increasingly Blow The Whistle After Bio-Rad Verdict
• Report Details Problems At Theranos' Arizona Lab
• Fed. Circ. OKs Invalidity Of Patent In $37.5M Greatbatch Case
• GAO Singles Out Holes In FDA Adverse Event Reporting
• Vaccines Developer Visterra Postpones $50M IPO
• AbbVie Fights Discovery Request Of Doc In Testosterone MDL
• GE Doubles Down On DQ Dispute In Incubator Patent Case
• Del. Justices Uphold Volcano's 'Irrebuttable' Merger Rule
• Big Pharma Challenges FDA's New Off-Label Rule
• USPTO Asks Fed. Circ. For Fee Awards In All Outside Suits
• Sloan Kettering Seeks More Sanctions In Drug IP Case
• Don't Overlook Pleading Challenges In State Pharma Suits
• Key Takeaways From FTC Merger Remedy Study
• Law Firm Margin Improvement: The Long Game
• Gore Must Pay Fees After Sanctions Bid Fails In IP Row
• Fresenius Drug Killed Dialysis Patient, Jury Told
• Stakes High For J&J At Start Of Latest Baby Powder Trial
• Fed. Circ. Lets Sanofi, Regeneron Sell Drug In Patent Appeal
• What To Watch As FTC Opens New Front On Generic Delays
• Kimberly-Clark, Gown Buyers Want Experts, Evidence Blocked
• Former NFL Star Sues Hair Clinic Over Use Of Likeness
• Shkreli Involved In Tech Startup Looking To Raise $1M
• FTC, Valeant See Eye-To-Eye On Paragon Divestiture
• Del. Justices Grapple With Volcano's 'Irrebuttable' Rule
• US Intervenes In Blood Pressure Drug Antitrust Suit
• Teva Sub Says It Should Also Be Cut From FTC Androgel Suit
• Pharma Rep Avoids Prison For Lying To Feds Over Kickbacks
• Pharma Co. Investors Sue After CEO Detained Over Drug Trial
• Medtronic Bone Mill Antitrust Suit Barred, 10th Circ. Says
• 1st Circ. To Size Up Antitrust Shield In Enoxaparin Row
• DOJ Criminal Division In 2016: Fraud Section Rising
• Meister Seelig Adds IP Partner From Haynes And Boone
• Justice Gorsuch And Product Liability Litigation
• Groups Sue To Block Trump's 2-For-1 Regulatory Order
• 2nd Circ. Revives Actos Antitrust Suit But Limits Scope
• 2017 Check-Up: Is Your Law Firm Positioned For Success?
• Pa. Judge Explains Bench Toss Of Paxil Birth Defect Suit
• Major Cos. Push High Court For Stricter Patent Venue Rules
• Cosmetics Trade Group Wants Out Of J&J Talc MDL
• Starboard Settlement Adds Fresh Faces To Perrigo's Board
• Another Biotech Director Arrested In Insider Trading Suit
• FDA Warning Wire: Dirty Dentures, Contact Lenses, Chocolate
• NuScience Fails To Show Atty. Malice In Trade Secrets Row
• Shire Unit Abused FDA Process With Most Filings Ever: FTC
• Lifewatch Must Turn Over Some Evidence Sought By FTC
• Posner Heaps Doubt On Glaucoma Dropper Class Claims
• Brazilian Airline Azul Leads 3 IPOs Joining Pipeline
• The Missing Key To 3rd-Party Litigation Funding
• Biomarker Exposure Tests Will Revolutionize Toxic Torts
• Trends To Watch In DOJ Cartel Investigations This Year
• What TC Heartland Could Mean For Venue In ANDA Cases
• How Stein Could Transform Sentencing For Securities Fraud
• Jury Awards Bio-Rad's Ex-GC $8M For Retaliatory Firing
• Alere Calls Abbott's Chancery Bid For Info Unfounded
• Ancestry.com To Pay $12.5M To Settle DNA Test Patent Suit
• Deadly Drugs Shipped Before Test Results Came In, Jury Told
• 2nd Circ. Resurrects TCPA Suit Over Faxed Seminar Invites
• Syringe Co. Asks Justices To Review $340M Antitrust Reversal
• Calif. AG Sues Allergan, Watson Over Pay-For-Delay Scheme
• Investors Sue Over Lilly's $960M Buy Of Migraine Drug Co.
• Monsanto Can't Escape Cities' PCBs Suit, Judge Rules
• Stemtech Pictures High Court Taking Up $1.6M Photo Case
• Stay Cymbalta Suit Until Xbox Ruling, Lilly Tells 9th Circ.
• GSK Nabs $40M Arbitral Award In Migraine Drug Row
• How PTAB Applies Mayo To Method Involving Natural Principle
• 11th Circ. Affirms CPA's Insider Trading Conviction
• Mylan Inks $96.5M Pay-For-Delay Deal With Cephalon Buyers
• Teva Facing Infringement Suit Over Generic Pain Med ANDA
• GSK Says New Claim Has No Evidence In Avandia MDL
• Derma Sciences Hit With Another Suit Over Integra Buy
• AstraZeneca Prevails In Trial Over Diabetes Drug Patent
• CVS' Shoddy Shipping Ruined Arthritis Drug, Suit Says
• GSK Refuses Judge's Order In Reed Smith Suicide Trial
• How To Ask A Jury For Money
• Express Scripts Loses Quick Win Bid In Antitrust Suit
• Hagens Berman Objects To Report On Thalidomide Suits
• Spain Opens Antitrust Proceedings Against Drugmaker Aspen
• FDA To Divulge Full Resumes Of Outside Advisers
• Wiley Rein Adds Enviro & Safety, Product Reg Attys
• Nature's Way Gets Quick Win In Ginkgo Pill Suit
• UK Enforcement Chief Warns Antitrust Probes Won't Slow
• Seyfarth Adds IP Partner To DC Litigation Group
• What Schulhauser Means For Conditional Claim Limitations
• Clearing Up The Smoke: Insurance And Marijuana
• Affirmed: Pharmacies Are Not Liable For Drug Labeling
• 11th Circ. Bats Down Atty's Fight For $1M In Billing Row
• DNA Testing Co. Balks At Class Cert. In Row Over Web Posts
• Trump Gets Scant Support On Eased FDA Oversight
• FTC Asks To Drop Par, Paddock From AndroGel Antitrust Row
• United Healthcare's Hep C Coverage Deal Gets Final OK
• FDA Warns Of Serious Allergic Reactions To Antiseptic
• Abbott Cleared Of All Claims In Depakote Birth-Defects Trial
• Lifewatch Fights FTC's Discovery Request In Marketing Suit
• Real Estate Rumors: New York Times, Apotex, Square Mile
• NY Fed. Judge Throws Out Arsenic Cleanup Suit
• Becton Can't Get Coverage For Syringe Antitrust Suit: Insurer
• Deals Rumor Mill: ChemChina, Nature's Bounty, Pfizer
• Davis Polk Partner Testifies Bio-Rad GC Didn't Back Claims
• Ardian Unloads Disinfectant Biz To Ecolab In $809M Deal
• Avandia MDL Settlement Administrator Sues Atty For $2.5M
• Biotech Co. Suspends $150M IPO, Citing Market Jitters
• Mylan Slams IRS' 'Misleading' Discovery Motion In Tax Row
• A $15M Lesson On Merger Talk Disclosure
• An Open Letter To The New FTC Chair On Pyramid Schemes
• Can Federal Agencies Reverse Course Under Trump?
• The 4 Wittiest Dissents By Gorsuch
• NY Investor Blocks Transfer Of Keryx Stock Drop Suit
• Gorsuch's Opening Words Speak Volumes About His Style
• Bio-Rad GC's Temper, Damages Claim Questioned At Trial
• REIT's $1.5B IPO Thrusts 1 Firm Ahead Of Pack In Jan.
• Senators Flirt With Nuclear Option Over High Court Pick
• HHS Ices 340B 'Mega-Guidance' Amid Regulatory Freeze
• Biotech Co. Must Face Willful Infringement, Judge Says
• Taylor-Wharton Attys, Advisers Get $4M In Ch. 11 Fees
• Similar On The Law, Gorsuch Differs From Scalia In Style
• Drug Refund Co. Slams $116M Theft Claims In Trial Opener
• Attys React To Judge Gorsuch's Supreme Court Nomination
• Deals Rumor Mill: Arqiva, Medtronic, CCC
• Mayer Brown Adds IP Partner From Clifford Chance
• J&J's Hip Verdict Appeal Attacks 'Inflammatory' Rhetoric
• Derma Sciences Hit With Suits Over $204M Integra Buy
• Benicar MDL Judge Won't Send Med Mal Suit To State Court
• Stradley Ronon Lands Ex-Pepper Hamilton IP Attorney
• The Myth Of The Forceful Mediator
• Tips For Addressing The IP Challenges Of 3-D Printing: Part 1
• Why The Supreme Court Must Revisit Personal Jurisdiction